Influence of physical activity on the immune system in breast cancer patients during chemotherapy.
CONCLUSION: Chemotherapy led to a decrease in nearly all measured immune cells. In this study, physical intervention with endurance or resistance training did not suppress cellular immunity any further. Larger multicenter trials are needed to evaluate the exact impact of sports intervention on immune cell subpopulations. PMID: 29305709 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - January 5, 2018 Category: Cancer & Oncology Authors: Schmidt T, Jonat W, Wesch D, Oberg HH, Adam-Klages S, Keller L, Röcken C, Mundhenke C Tags: J Cancer Res Clin Oncol Source Type: research

Isolated breast metastasis from gastric cancer in a male patient.
Abstract A 72-year-old man underwent total gastrectomy for gastric cancer (por2, T3, N2, Stage IIIA). Eleven courses of postoperative chemotherapy with TS-1 (tegafur/gimeracil/oteracil) were administered. Five months after surgery, the serum carcinoembryonic antigen value was slightly elevated. However, computed tomography did not reveal any metastatic lesions in other organs. Two years after surgery, the patient felt a mass in the left mammary. A 2-cm tumor was palpable in the central portion of the breast. Ultrasonography revealed a hypoechoic tumor, which was Class 3 on aspiration biopsy cytological examination...
Source: Clinical Breast Cancer - January 4, 2018 Category: Cancer & Oncology Authors: Kubo H, Shimizu T, Sekido H, Matsuda G, Takeda K, Watanabe A, Sakamoto R, Yamamoto Y, Toyoda J, Niino H Tags: Clin J Gastroenterol Source Type: research

Risk factors for unplanned discontinuation of scheduled treatment in elderly patients with castration-resistant prostate cancer: results of the IBuTu study.
ch L Abstract PURPOSE: To gain knowledge about the factors associated with discontinuation of scheduled treatment in elderly men with castration-resistant prostate cancer (CRPC). METHODS: Patients ≥ 70 years with CRPC starting a new line of treatment were included in a prospective cohort study. A geriatric assessment (CGA) was performed at baseline, including comorbidity, mobility, functional/mental/nutritional status, as well as depression. Furthermore, pain intensity, quality of life, ECOG-performance status, and physicians' and patients' perception of health were documented. Reasons f...
Source: Clinical Breast Cancer - January 4, 2018 Category: Cancer & Oncology Authors: Honecker F, Wedding U, Kallischnigg G, Schroeder A, Klier J, Frangenheim T, Weißbach L Tags: J Cancer Res Clin Oncol Source Type: research

Association of Cell-Free DNA Tumor Fraction and Somatic Copy Number Alterations With Survival in Metastatic Triple-Negative Breast Cancer.
Abstract Purpose Cell-free DNA (cfDNA) offers the potential for minimally invasive genome-wide profiling of tumor alterations without tumor biopsy and may be associated with patient prognosis. Triple-negative breast cancer (TNBC) is characterized by few mutations but extensive somatic copy number alterations (SCNAs), yet little is known regarding SCNAs in metastatic TNBC. We sought to evaluate SCNAs in metastatic TNBC exclusively via cfDNA and determine if cfDNA tumor fraction is associated with overall survival in metastatic TNBC. Patients and Methods In this retrospective cohort study, we identified 164 patients...
Source: Clinical Breast Cancer - January 3, 2018 Category: Cancer & Oncology Authors: Stover DG, Parsons HA, Ha G, Freeman SS, Barry WT, Guo H, Choudhury AD, Gydush G, Reed SC, Rhoades J, Rotem D, Hughes ME, Dillon DA, Partridge AH, Wagle N, Krop IE, Getz G, Golub TR, Love JC, Winer EP, Tolaney SM, Lin NU, Adalsteinsson VA Tags: J Clin Oncol Source Type: research

Circulating Tumor DNA Guides Prognosis in Metastatic Triple-Negative Breast Cancer.
PMID: 29298118 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - January 3, 2018 Category: Cancer & Oncology Authors: Zivanovic Bujak A, Dawson SJ Tags: J Clin Oncol Source Type: research

Descriptions of Fundamental Care needs in cancer care - an exploratory study.
CONCLUSION: Some people with a cancer diagnosis have to strive for help and support from the nursing staff to manage to regain control over their recovery. Nurses in cancer care need to focus on the patients' fundamental care needs to optimise their patients' recovery. This article is protected by copyright. All rights reserved. PMID: 29292542 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - January 2, 2018 Category: Cancer & Oncology Authors: Muntlin Athlin Å, Browall M, Wengström Y, Conroy T, Kitson AL Tags: J Clin Nurs Source Type: research

Reply to E. Ramos et al.
PMID: 29293390 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - January 2, 2018 Category: Cancer & Oncology Authors: Hughes KS Tags: J Clin Oncol Source Type: research

No association between the risk of breast cancer and systemic lupus erythematosus: evidence from a meta-analysis.
Abstract Several studies have estimated breast cancer risk in patients with systemic lupus erythematosus (SLE) relative to the general population. However, the results have been inconclusive. Therefore, we conducted a meta-analysis to ascertain a more comprehensive conclusion. A systematic literature search of electronic databases including PubMed, Web of Science, Embase, Cochrane Library, and Scopus was conducted to identify eligible studies using multiple search strategies. Based on the degree of heterogeneity, a random-effect model was chosen to calculate the pooled standardized incidence rate (SIR) with 95% co...
Source: Clinical Breast Cancer - January 2, 2018 Category: Cancer & Oncology Authors: Rezaieyazdi Z, Tabaei S, Ravanshad Y, Akhtari J, Mehrad-Majd H Tags: Clin Rheumatol Source Type: research

Correction to: Recommendations for the follow-up care of female breast cancer survivors: a guideline of the Spanish Society of Medical Oncology (SEOM), Spanish Society of Primary Care Physicians (SEMERGEN), Spanish Society for Family and Community Medicine (SEMFYC), Spanish Society for General and Family Physicians (SEMG), Spanish Society of Obstetrics and Gynecology (SEGO), Spanish Society of Radiation Oncology (SEOR), Spanish Society of Senology and Breast Pathology (SESPM), and Spanish Society of Cardiology (SEC).
dez T Abstract Correction to: Clin Transl Oncol https://doi.org/10.1007/s12094-017-1801-4. PMID: 29294225 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - January 2, 2018 Category: Cancer & Oncology Authors: Barnadas A, Algara M, Cordoba O, Casas A, Gonzalez M, Marzo M, Montero A, Muñoz M, Ruiz A, Santolaya F, Fernandez T Tags: Clin Transl Oncol Source Type: research

Considerations in Testing for Inherited Breast Cancer Predisposition in the Era of Personalized Medicine.
This article provides an overview of individuals at risk for inherited cancer predisposition and recommendations for surveillance and management. PMID: 29132555 [PubMed - in process] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - November 16, 2017 Category: Cancer & Oncology Authors: Powers B, Pal T, Laronga C Tags: Surg Oncol Clin N Am Source Type: research

Neoadjuvant Endocrine Therapy: Who Benefits Most?
Abstract Neoadjuvant endocrine therapy (NET) can be effective at downstaging patients with estrogen receptor-positive tumors and identifying those tumors that are endocrine sensitive and resistant. The optimal prognostic markers for stratification are under investigation. Use of NET will allow the identification of patients with estrogen receptor-positive tumors who might benefit from additional treatment and allow better understanding of endocrine resistance. PMID: 29132556 [PubMed - in process] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - November 16, 2017 Category: Cancer & Oncology Authors: Grossman J, Ma C, Aft R Tags: Surg Oncol Clin N Am Source Type: research

Triple-Negative Breast Cancer: Who Should Receive Neoadjuvant Chemotherapy?
Abstract Progress in the treatment of triple-negative breast cancer remains an important challenge. Given the aggressive biology and high risk of distant recurrence, systemic chemotherapy is warranted in most patients. Neaodjuvant chemotherapy benefits patients with locally advanced disease by downsizing the tumor and increasing the probability of breast-conserving surgery. Clinical and pathologic responses provide important prognostic information, which makes neoadjuvant therapy an attractive approach for all patients with triple-negative breast cancer. Clinical research in the neoadjuvant setting is focused on i...
Source: Clinical Breast Cancer - November 16, 2017 Category: Cancer & Oncology Authors: Chaudhary LN, Wilkinson KH, Kong A Tags: Surg Oncol Clin N Am Source Type: research

Intraoperative Margin Assessment in Breast Cancer Management.
Abstract The goal of breast-conserving surgery is to excise the tumor with negative margins while achieving a successful cosmetic result. Although it is not feasible to have re-excision rates of zero, several techniques have been described to reduce the need for a return to the operating room. When rates of re-excision are high, consideration should be given to using 1 or more of these techniques. It is critical that re-excision rates are tracked when new techniques are implemented to ensure progress. In addition, attention must be paid to ensuring that cosmetic outcomes remain optimal. PMID: 29132558 [PubMed...
Source: Clinical Breast Cancer - November 16, 2017 Category: Cancer & Oncology Authors: Reyna C, DeSnyder SM Tags: Surg Oncol Clin N Am Source Type: research

Oncoplastic Breast Reconstruction: Should All Patients be Considered?
Abstract Oncoplastic surgery of the tissue defect from partial mastectomy should be considered for all patients. It can result in in significant asymmetries from scar contraction, skin tethering, and alterations in the nipple areolar complex location. Indications, risks, and benefits are discussed. Optimal procedures are described, considering resected specimen volume, primary tumor location, tumor to breast size ratio, and the impact on the nipple areolar complex. Indications for plastic surgery consultation and joint surgery are discussed. Surgical management includes incision planning, preservation of the nippl...
Source: Clinical Breast Cancer - November 16, 2017 Category: Cancer & Oncology Authors: Habibi M, Broderick KP, Sebai ME, Jacobs LK Tags: Surg Oncol Clin N Am Source Type: research

Alternatives to Standard Fractionation Radiation Therapy After Lumpectomy: Hypofractionated Whole-Breast Irradiation and Accelerated Partial-Breast Irradiation.
Abstract Adjuvant whole-breast irradiation (WBI) after lumpectomy has been an established standard of care for decades. Standard-fractionation WBI delivered over 5 to 7 weeks can achieve durable tumor control with low toxicity but can be inconvenient for patients and cost ineffective. Hypofractionated WBI can be completed in 3 to 4 weeks and, based on long-term randomized data, is the preferred standard of care in select patients. Accelerated partial-breast irradiation can be delivered using even shorter treatment regimens. Although the available data on accelerated partial-breast irradiation is more lim...
Source: Clinical Breast Cancer - November 16, 2017 Category: Cancer & Oncology Authors: Ohri N, Haffty BG Tags: Surg Oncol Clin N Am Source Type: research

Breast Cancer Disparities: How Can We Leverage Genomics to Improve Outcomes?
Abstract Breast cancer mortality rates are higher in African American compared with white American women. Disproportionately rising incidence rates, coupled with higher rates of biologically aggressive disease among African Americans is resulting in a widening of the mortality disparity. Higher rates of triple-negative breast cancer among African American women, as well as women from western sub-Saharan Africa, has prompted questions regarding the role of African ancestry as a marker of hereditary susceptibility for specific disease phenotypes. Advances in germline genetics, as well as somatic tumor genomic resear...
Source: Clinical Breast Cancer - November 16, 2017 Category: Cancer & Oncology Authors: Davis MB, Newman LA Tags: Surg Oncol Clin N Am Source Type: research

When Does Atypical Ductal Hyperplasia Require Surgical Excision?
Abstract Atypical ductal hyperplasia (ADH) is a proliferative, nonobligate precursor breast lesion and a marker of increased risk for breast carcinoma. Surgical excision remains the standard recommendation following a core needle biopsy result consistent with ADH. Recent research suggests that women with no mass lesion or discordance, removal of greater than or equal to 90% of calcifications at the time of core needle biopsy, involvement of less than or equal to 2 terminal duct lobular units, and absence of cytologic atypia or necrosis are likely to have a less than 5% chance of a missed cancer. PMID: 2913256...
Source: Clinical Breast Cancer - November 16, 2017 Category: Cancer & Oncology Authors: Racz JM, Degnim AC Tags: Surg Oncol Clin N Am Source Type: research

Tomosynthesis in Breast Cancer Imaging: How Does It Fit into Preoperative Evaluation and Surveillance?
Abstract An important limitation of conventional two-dimensional mammography is the overlap of dense breast tissue obscuring masses. Digital breast tomosynthesis (DBT) has emerged as a mammographic technology that overcomes this limitation and is considered an overall better mammogram. DBT has been shown to detect significantly more breast cancer than conventional two-dimensional mammography, and to decrease the number of callbacks for diagnostic evaluation from screening mammography. Usually the callback evaluation is deemed to be overlap of tissue requiring no further management. DBT is used in the screening and...
Source: Clinical Breast Cancer - November 16, 2017 Category: Cancer & Oncology Authors: Eghtedari M, Tsai C, Robles J, Blair SL, Ojeda-Fournier H Tags: Surg Oncol Clin N Am Source Type: research

Anatomy and Breast Cancer Staging: Is It Still Relevant?
Abstract Breast cancer staging concisely summarizes disease status, creating a framework for assessing and relaying prognostic information. The fundamental concepts and components of breast cancer staging are reviewed. The AJCC Cancer Staging Manual, which includes traditional anatomic factors, now includes additional tumor characteristics: tumor grade, estrogen receptor status, progesterone receptor status, human epidermal growth factor receptor 2 status, and (when available) multigene panel testing from the primary tumor. With these updates, staging provides the most reliable system for accurately predicting pat...
Source: Clinical Breast Cancer - November 16, 2017 Category: Cancer & Oncology Authors: Plichta JK, Campbell BM, Mittendorf EA, Hwang ES Tags: Surg Oncol Clin N Am Source Type: research

Are There Alternative Strategies for the Local Management of Ductal Carcinoma in Situ?
Abstract The management of ductal carcinoma in situ (DCIS) has traditionally followed the evidence base for invasive breast cancer using surgery, radiation therapy, and drug therapy to remove the DCIS from the breast and reduce the risk of recurrence for both DCIS and invasive breast cancer. Because of concerns regarding the overtreatment of DCIS, randomized controlled trials have been established to test the outcomes (invasive breast cancer outcomes and patient-reported outcome measures) of active surveillance compared with guideline-concordant care for low-risk (for progression) DCIS. These strategies are u...
Source: Clinical Breast Cancer - November 16, 2017 Category: Cancer & Oncology Authors: Rosso KJ, Weiss A, Thompson AM Tags: Surg Oncol Clin N Am Source Type: research

Lobular Breast Cancer: Different Disease, Different Algorithms?
Abstract Invasive lobular carcinoma (ILC) is the second most common type of breast cancer, with a unique pathogenesis and distinct clinical biology. ILCs display a characteristic loss of E-cadherin, are largely estrogen receptor positive, HER2 negative, and low to intermediate grade. These features portend a favorable prognosis, but there is a tendency for late recurrences and atypical metastases. ILCs tend to be insidious and infiltrative, which can pose a challenge for diagnosis, and emerging data suggest they may have a propensity for a differing response to standard therapies. PMID: 29132567 [PubMed - in ...
Source: Clinical Breast Cancer - November 16, 2017 Category: Cancer & Oncology Authors: Mamtani A, King TA Tags: Surg Oncol Clin N Am Source Type: research

Innovation in the Diagnosis and Management of Breast Cancer.
PMID: 29132569 [PubMed - in process] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - November 16, 2017 Category: Cancer & Oncology Authors: Pawlik TM Tags: Surg Oncol Clin N Am Source Type: research

Integrating New Knowledge and Surgical Innovation into the Diagnosis and Management of Breast Cancer.
PMID: 29132570 [PubMed - in process] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - November 16, 2017 Category: Cancer & Oncology Authors: Hunt KK Tags: Surg Oncol Clin N Am Source Type: research

Modern Approaches to the Surgical Management of Malignant Breast Disease: The Role of Breast Conservation, Complete Mastectomy, Skin- and Nipple-Sparing Mastectomy.
This article provides an overview of these modern surgical approaches for breast cancer treatment. PMID: 29080650 [PubMed - in process] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - November 1, 2017 Category: Cancer & Oncology Authors: Cil TD, McCready D Tags: Clin Plast Surg Source Type: research

Indications and Controversies in Lipofilling for Partial Breast Reconstruction.
Abstract The treatment of sequelae after conservative breast cancer treatment can be a challenge. Lipomodeling, although controversial in the beginning, is a safe technique that can help in the treatment of these deformities, without an important impact on the imaging surveillance. Depending on the severity of the deformity, one or several sessions of fat transfer can be required. The technique is easy and reproducible, but before obtaining satisfying results with a low complication rate, a learning curve should be completed. The final result is natural, with normal breast consistency, with no additional scars. ...
Source: Clinical Breast Cancer - November 1, 2017 Category: Cancer & Oncology Authors: Delay E, Guerid S, Meruta AC Tags: Clin Plast Surg Source Type: research

Risk-Reducing Mastectomy and Breast Reconstruction: Indications and Evidence for Current Management Strategies.
Abstract Breast cancer affects nearly every woman either personally or through a family member or friend. Awareness of associated familial and genetic risks has been steadily increasing over the last decade. Bilateral risk-reduction mastectomy seeks to decrease the incidence and mortality of breast cancer in women without abnormality but with elevated risk of developing cancer. Contralateral risk-reduction mastectomy aims to decrease the incidence of contralateral breast cancer in women diagnosed with unilateral breast cancer. As understanding improves and techniques progress, the relative merits of surgical risk ...
Source: Clinical Breast Cancer - November 1, 2017 Category: Cancer & Oncology Authors: Eisemann BS, Spiegel AJ Tags: Clin Plast Surg Source Type: research

Patient-Centered Breast Reconstruction Based on Health-Related Quality-of-Life Evidence.
Abstract The article summarizes the available evidence regarding clinical decision making in breast reconstruction from the patient perspective of satisfaction and health-related quality of life. A review of generic and specific patient reported outcome measures is provided. Important components of breast reconstruction care are compared, such as timing of reconstruction, autologous and implant-based reconstruction, and the use of nipple-sparing and skin-sparing mastectomy. This evidence-based summary will be useful to guide clinicians when discussing breast reconstruction with their patients. PMID: 29080656 ...
Source: Clinical Breast Cancer - November 1, 2017 Category: Cancer & Oncology Authors: Platt J, Zhong T Tags: Clin Plast Surg Source Type: research

Neoadjuvant Chemotherapy for Breast Cancer Treatment and the Evidence-Based Interaction with Immediate Autologous and Implant-Based Breast Reconstruction.
This article aims to determine the impact of neoadjuvant chemotherapy on immediate breast reconstruction by assessing their compatibility for oncological safety and the incidence and management of postoperative complications. A review of scientific publications published between 2009 and 2017 was undertaken. The relationship between neoadjuvant chemotherapy and immediate breast reconstruction was analyzed to compile and assess the potential interaction between the procedures. The search was limited to English language publications, but there were no limiting factors at the level of study typology. Full-text articles, inclu...
Source: Clinical Breast Cancer - November 1, 2017 Category: Cancer & Oncology Authors: Riba J, de Romani SE, Masia J Tags: Clin Plast Surg Source Type: research

Indications and Controversies in Partial Mastectomy Defect Reconstruction.
This article describes the authors' many years of experience of breast cancer treatment using oncoplastic surgery. They also established a decision-making guide, whose implementation enables treatment of every patient. PMID: 29080658 [PubMed - in process] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - November 1, 2017 Category: Cancer & Oncology Authors: Honart JF, Reguesse AS, Struk S, Sarfati B, Rimareix F, Alkhashnam H, Kolb F, Rem K, Leymarie N Tags: Clin Plast Surg Source Type: research

Clinical utility of a self-administered questionnaire for assessment of hereditary gynecologic cancer.
Conclusions: In this study, we were able to show that the newly designed questionnaire is a useful tool for evaluating cancer family history along with Society of Gynecologic Oncology criteria or Amsterdam criteria II. When considering the risk of Lynch syndrome for a patient with ovarian cancer, it is important to collect a second and third relative's family history. PMID: 28334914 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - March 24, 2017 Category: Cancer & Oncology Authors: Masuda K, Hirasawa A, Irie-Kunitomi H, Akahane T, Ueki A, Kobayashi Y, Yamagami W, Nomura H, Kataoka F, Tominaga E, Banno K, Susumu N, Aoki D Tags: Jpn J Clin Oncol Source Type: research

The antineoplastic drug, trastuzumab, dysregulates metabolism in iPSC-derived cardiomyocytes.
Abstract BACKGROUND: The targeted ERBB2 therapy, trastuzumab, has had a tremendous impact on management of patients with HER2+ breast cancer, leading to development and increased use of further HER2 targeted therapies. The major clinical side effect is cardiotoxicity but the mechanism is largely unknown. On the basis that gene expression is known to be altered in multiple models of heart failure, we examined differential gene expression of iPSC-derived cardiomyocytes treated at day 11 with the ERBB2 targeted monoclonal antibody, trastuzumab for 48 h and the small molecule tyrosine kinase inhibitor of EGFR and...
Source: Clinical Breast Cancer - January 21, 2017 Category: Cancer & Oncology Authors: Necela BM, Axenfeld BC, Serie DJ, Kachergus JM, Perez EA, Thompson EA, Norton N Tags: Clin Transl Med Source Type: research

Final report of KSCC0803: feasibility study of capecitabine as adjuvant chemotherapy for stage III colon cancer in Japan.
CONCLUSIONS: The survival results in this study are in line with those of previously reported, reliable, studies. The safety and tolerability of the protocol regimen have already been confirmed. Oral capecitabine is acceptable as adjuvant chemotherapy for Japanese patients with resected stage III colon cancer. PMID: 28101757 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - January 17, 2017 Category: Cancer & Oncology Authors: Minami K, Morita M, Emi Y, Okamoto M, Tanaka E, Nagata S, Touyama T, Ohgaki K, Tanaka T, Okumura H, Suenaga T, Tokunaga S, Oki E, Kakeji Y, Akagi Y, Baba H, Natsugoe S, Maehara Y, Kyushu Study Group of Clinical Cancer (KSCC) Tags: Int J Clin Oncol Source Type: research

Mammary Gland Involution Provides a Unique Model to Study the TGF- β Cancer Paradox.
This article reviews facets of mammary gland involution that are TGF-β regulated, namely mammary epithelial cell death, immune activation, and extracellular matrix remodeling. We outline how distinct cellular responses and crosstalk between cell types during physiologically normal mammary gland involution contribute to simultaneous tumor suppressive and promotional microenvironments. We also highlight alternatives to direct TGF-β blocking anti-cancer therapies with an emphasis on eliciting concerted microenvironmental-mediated tumor suppression. PMID: 28098775 [PubMed - in process] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - January 12, 2017 Category: Cancer & Oncology Authors: Guo Q, Betts C, Pennock N, Mitchell E, Schedin P Tags: J Clin Med Source Type: research

The outcomes of radiotherapy and factors that predict overall survival in elderly patients with esophageal squamous cell carcinoma.
CONCLUSION: Radiation therapy in elderly patients (≥70 years) can not only obtain good treatment result, but also make patients have better tolerance and reduce the risk of complications. Radiotherapy should be as a primary treatment option for elderly patients with inoperable ESCC. PMID: 28091898 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - January 12, 2017 Category: Cancer & Oncology Authors: Yin H, E M, Zhang H, Wang C Tags: Clin Transl Oncol Source Type: research

Angiotensin receptor blockers and the risk of cancer: data mining of a spontaneous reporting database and a claims database 
.
CONCLUSIONS: Significant inverse association was found between ARB use and all cancer types assessed as a whole. However, in the analyses of individual cancers, the risks of ARB-induced cancer may differ according to cancer site. It may be reasonable to assume that the risks of ARB-induced cancer may differ according to cancer site.
. PMID: 28079518 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - January 11, 2017 Category: Cancer & Oncology Authors: Fujimoto M, Kanou M, Hosomi K, Takada M Tags: Int J Clin Pharmacol Ther Source Type: research

Convergent and criterion validity of the CogState computerized brief battery cognitive assessment in women with and without breast cancer.
CONCLUSIONS: The results provide preliminary support for further research to determine if the CogState tests are viable as screening tools to detect subtle cognitive differences between breast cancer survivors and healthy women. Our study was limited by the low base rate of cognitive impairment and small sample size. We recommend further research employing sufficiently powered sample sizes and a longitudinal, repeated measures study design. PMID: 28080264 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - January 11, 2017 Category: Cancer & Oncology Authors: Patel SK, Meier AM, Fernandez N, Lo TT, Moore C, Delgado N Tags: Clin Neuropsychol Source Type: research

Patient-Specific Circulating Tumor DNA Detection during Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.
Abstract BACKGROUND: In nonmetastatic triple-negative breast cancer (TNBC) patients, we investigated whether circulating tumor DNA (ctDNA) detection can reflect the tumor response to neoadjuvant chemotherapy (NCT) and detect minimal residual disease after surgery. METHODS: Ten milliliters of plasma were collected at 4 time points: before NCT; after 1 cycle; before surgery; after surgery. Customized droplet digital PCR (ddPCR) assays were used to track tumor protein p53 (TP53) mutations previously characterized in tumor tissue by massively parallel sequencing. RESULTS: Forty-six patients with nonmetastati...
Source: Clinical Breast Cancer - January 9, 2017 Category: Cancer & Oncology Authors: Riva F, Bidard FC, Houy A, Saliou A, Madic J, Rampanou A, Hego C, Milder M, Cottu P, Sablin MP, Vincent-Salomon A, Lantz O, Stern MH, Proudhon C, Pierga JY Tags: Clin Chem Source Type: research

Paper-Based MicroRNA Expression Profiling from Plasma and Circulating Tumor Cells.
CONCLUSIONS: Overall, this paper-based extraction method enables an efficient, cost-effective workflow for maximized recovery of small RNAs from limited biological samples for downstream molecular analyses. PMID: 28073899 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - January 9, 2017 Category: Cancer & Oncology Authors: Leong SM, Tan KM, Chua HW, Huang MC, Cheong WC, Li MH, Tucker S, Koay ES Tags: Clin Chem Source Type: research

Estimate of false-positive breast cancer diagnoses from accuracy studies: a systematic review.
CONCLUSIONS: High heterogeneity of the included studies precluded formal pooling estimates. When considering studies of higher sample size or methodological quality, false-positive rates and MBM are around 1%. The impact of false-positive histological diagnoses of breast cancer on unnecessary treatment, as well as that of overdiagnosis, is not negligible and is of importance in clinical practice. PMID: 28073996 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - January 9, 2017 Category: Cancer & Oncology Authors: Segnan N, Minozzi S, Ponti A, Bellisario C, Balduzzi S, González-Lorenzo M, Gianola S, Armaroli P Tags: J Clin Pathol Source Type: research

Peculiarities of the obese patient with cancer: a national consensus statement by the Spanish Society for the Study of Obesity and the Spanish Society of Medical Oncology.
lmeida JM, Barneto I, Goday A Abstract The relationship between obesity and cancer is clear and is present at all times during course of the disease. The importance of obesity in increasing the risk of developing cancer is well known, and some of the most prevalent tumours (breast, colorectal, and prostate) are directly related to this risk increase. However, there is less information available on the role that obesity plays when the patient has already been diagnosed with cancer. Certain data demonstrate that in some types of cancer, obese patients tolerate the treatments more poorly. Obesity is also known to hav...
Source: Clinical Breast Cancer - January 9, 2017 Category: Cancer & Oncology Authors: Pérez-Segura P, Palacio JE, Vázquez L, Monereo S, de Las Peñas R, de Icaya PM, Grávalos C, Lecube A, Blasco A, García-Almeida JM, Barneto I, Goday A Tags: Clin Transl Oncol Source Type: research

Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2-Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study.
Conclusion T-DM1 showed noninferior, but not superior, efficacy and better tolerability than did taxane plus trastuzumab for first-line treatment of HER2-positive, advanced breast cancer. PMID: 28056202 [PubMed - in process] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - January 7, 2017 Category: Cancer & Oncology Authors: Perez EA, Barrios C, Eiermann W, Toi M, Im YH, Conte P, Martin M, Pienkowski T, Pivot X, Burris H, Petersen JA, Stanzel S, Strasak A, Patre M, Ellis P Tags: J Clin Oncol Source Type: research

Association Between Out-Of-Pocket Costs, Race/Ethnicity, and Adjuvant Endocrine Therapy Adherence Among Medicare Patients With Breast Cancer.
This study aimed to determine whether there are racial/ethnic differences in 1-year adherence to AET and whether out-of-pocket costs explain the racial/ethnic disparities in adherence. Methods This retrospective cohort study used the SEER-Medicare linked database to identify patients ≥ 65 years of age with hormone receptor-positive breast cancer who were enrolled in Medicare Part D from 2007 to 2009. The cohort included non-Hispanic whites, blacks, Hispanics, and Asians. Out-of-pocket costs for AET medications were standardized for a 30-day supply. Adherence to tamoxifen, aromatase inhibitors (AIs), and overall AET (tam...
Source: Clinical Breast Cancer - December 31, 2016 Category: Cancer & Oncology Authors: Farias AJ, Du XL Tags: J Clin Oncol Source Type: research

Persistent Breast Pain Among Women With Histories of Breast-conserving Surgery for Breast Cancer Compared With Women Without Histories of Breast Surgery or Cancer.
This study compared persistent breast pain among women who received breast-conserving surgery for breast cancer and women without a history of breast cancer. METHODS: Breast cancer survivors (n=200) were recruited at their first postsurgical surveillance mammogram (6 to 15 mo postsurgery). Women without a breast cancer history (n=150) were recruited at the time of a routine screening mammogram. All women completed measures of breast pain, pain interference with daily activities and intimacy, worry about breast pain, anxiety symptoms, and depression symptoms. Demographic and medical information were also collected. ...
Source: Clinical Breast Cancer - December 8, 2016 Category: Cancer & Oncology Authors: Edmond SN, Shelby RA, Keefe FJ, Fisher HM, Schmidt JE, Soo MS, Skinner CS, Ahrendt GM, Manculich J, Sumkin JH, Zuley ML, Bovbjerg DH Tags: Clin J Pain Source Type: research

Prediction of Acute Postoperative Pain Following Breast Cancer Surgery Using the Pain Sensitivity Questionnaire: A Cohort Study.
Abstract OBJECTIVES: Previous studies have indicated that preoperative pain sensitivity correlates with postoperative pain intensity, and thus may be used to predict severe postoperative pain. Self-rating of pain sensitivity using the "Pain Sensitivity Questionnaire (PSQ)" may be an adjunct to these measures. METHODS: We tested the predictive ability of the PSQ as well as experimental parameters of pain sensitivity and other known risk factors for acute pain in 198 patients scheduled for breast cancer surgery. A multivariable logistic regression model was created for the binary outcome "maximum...
Source: Clinical Breast Cancer - December 8, 2016 Category: Cancer & Oncology Authors: Rehberg B, Mathivon S, Combescure C, Mercier Y, Savoldelli GL Tags: Clin J Pain Source Type: research

Molecular Imaging and Precision Medicine in Breast Cancer.
Abstract Precision medicine, basing treatment approaches on patient traits and specific molecular features of disease processes, has an important role in the management of patients with breast cancer as targeted therapies continue to improve. PET imaging offers noninvasive information that is complementary to traditional tissue biomarkers, including information about tumor burden, tumor metabolism, receptor status, and proliferation. Several PET agents that image breast cancer receptors can visually demonstrate the extent and heterogeneity of receptor-positive disease and help predict which tumors are likely to re...
Source: Clinical Breast Cancer - November 21, 2016 Category: Cancer & Oncology Authors: Chudgar AV, Mankoff DA Tags: PET Clin Source Type: research

Localization of tamoxifen in human breast cancer tumors by MALDI mass spectrometry imaging.
CONCLUSIONS: The experimental model was successfully applied on frozen tumor samples allowing for differentiation between ER groups based on distribution of tamoxifen. PMID: 26965929 [PubMed] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - March 13, 2016 Category: Cancer & Oncology Authors: Végvári Á, Shavkunov AS, Fehniger TE, Grabau D, Niméus E, Marko-Varga G Tags: Clin Transl Med Source Type: research

Hypothyroidism and hyperthyroidism and breast cancer risk: a nationwide cohort study.
CONCLUSIONS: We found an increased risk of breast cancer in women with hyperthyroidism and a slightly decreased risk in women with hypothyroidism indicating an association between thyroid function level and breast cancer risk. PMID: 26863886 [PubMed - in process] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - February 13, 2016 Category: Cancer & Oncology Authors: Søgaard M, Farkas DK, Ehrenstein V, Jørgensen JO, Dekkers OM, Sørensen HT Tags: Eur J Endocrinol Source Type: research

Identification of a founder BRCA1 mutation in the Moroccan population.
acute; G, Brunet J, Lázaro C Abstract Breast cancer (BC) is the most frequent cancer among women in Morocco. However, the role of the most prevalent BC-predisposing genes, BRCA1 and BRCA2, has been largely unexplored. To help define the role of BRCA1 in breast cancer in Morocco, we characterized the first potential BRCA1 founder mutation in this population. Genetic testing of BRCA1 and BRCA2 in BC high-risk families identified mutation BRCA1 c.5309G>T, p.(Gly1770Val) or G1770V in five independent families from Morocco, suggesting a founder effect. To confirm this hypothesis, haplotype construction was pe...
Source: Clinical Breast Cancer - February 10, 2016 Category: Cancer & Oncology Authors: Quiles F, Teulé À, Martinussen Tandstad N, Feliubadaló L, Tornero E, Del Valle J, Menéndez M, Salinas M, Wethe Rognlien V, Velasco A, Izquierdo A, Capellá G, Brunet J, Lázaro C Tags: Clin Genet Source Type: research

Current status of ultrasound-guided surgery in the treatment of breast cancer.
Abstract The primary goal of breast-conserving surgery (BCS) is to obtain tumour-free resection margins. Margins positive or focally positive for tumour cells are associated with a high risk of local recurrence, and in the case of tumour-positive margins, re-excision or even mastectomy are sometimes needed to achieve definite clear margins. Unfortunately, tumour-involved margins and re-excisions after lumpectomy are still reported in up to 40% of patients and additionally, unnecessary large excision volumes are described. A secondary goal of BCS is the cosmetic outcome and one of the main determinants of worse cos...
Source: Clinical Breast Cancer - February 10, 2016 Category: Cancer & Oncology Authors: Volders JH, Haloua MH, Krekel NM, Meijer S, van den Tol PM Tags: World J Clin Oncol Source Type: research

Historical review of the causes of cancer.
Abstract In the early 1900s, numerous seminal publications reported that high rates of cancer occurred in certain occupations. During this period, work with infectious agents produced only meager results which seemed irrelevant to humans. Then in the 1980s ground breaking evidence began to emerge that a variety of viruses also cause cancer in humans. There is now sufficient evidence of carcinogenicity in humans for human T-cell lymphotrophic virus, human immunodeficiency virus, hepatitis B virus, hepatitis C virus, human papillomavirus, Epstein-Barr virus, and human herpes virus 8 according to the International Ag...
Source: Clinical Breast Cancer - February 10, 2016 Category: Cancer & Oncology Authors: Blackadar CB Tags: World J Clin Oncol Source Type: research